Soluble TNFα blockade overcomes lapatinib resistance and induces an innate immune response in HER2-positive breast cancer
; Mauro, Florencia Luciana ; de Martino, Mara ; Roldán Deamicis, Agustina ; Mercogliano, María Florencia ; Elizalde, Patricia Virginia ; Schillaci, Roxana Otros responsables
Fecha
2020
Editorial
American Association for Cancer Research
Revista
Título del libro
Nombre del evento
AACR Virtual Annual Meeting 2020
Fecha del evento
2020-06-22
Institución organizadora
American Association for Cancer Research
ISSN
0008-5472
eISSN
1538-7445
ISBN
Idioma
Inglés
Tipo del evento
Reunión
Clasificación temática
Palabras clave
Resumen
Lapatinib (LAP), a dual EGFR/HER2 tyrosine kinase inhibitor, is used as second-line therapy in women with HER2+ breast cancer (BC), but less than 25% of the patients achieve an objective response. An alternative therapeutic approach is needed to overcome LAP resistance in women with metastatic HER2+ BC, particularly in patients with central nervous system (CNS) metastasis where large biological molecules are not effective.
Colecciones
Aprobación
Revisión
Complementado por
Referenciado por
Licencia Creative Commons
Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa
Identificadores
Soluble TNFα blockade overcomes lapatinib resistance and induces an innate immune response in HER2-positive breast cancer; AACR Virtual Annual Meeting 2020; en línea; Estados Unidos; 2020; 1913-1913
Altmétricas